Clinical Trial Update: Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, PK, and efficacy of CFZ533 in moderate to severe generalized myasthenia gravis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis Generalized

Drugs mentioned

• CFZ533

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myasthenia Gravis, Generalized | Phase 2 | Status: COMPLETED | Results posted: 2019-07-25